Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

Østgård, Lene Sofie Granfeldt; Medeiros, Bruno C.; Sengeløv, Henrik; Nørgaard, Mette; Andersen, Mette Klarskov; Dufva, Inge Høgh; Friis, Lone Smidstrup; Kjeldsen, Eigil; Marcher, Claus Werenberg; Preiss, Birgitte; Severinsen, Marianne Tang; Nørgaard, Jan Maxwell

doi:10.1200/jco.2014.60.0890

Cited by 371 publications

(241 citation statements)

References 36 publications

Supporting

Mentioning

221

Contrasting

Unclassified

Order By: Relevance

“…This enables and encourages the physicians to enroll intensive therapy eligible patients with comorbidity into these trials and permits readily translation of clinical trial results to broader AML cohorts. Similar to previously observed, presence of sAML or tAML negatively impacted enrollment into clinical trials, [12] at least in part, due to risk of excessive anthracycline exposure. These findings limit our understanding on therapeutic effects in these subgroups of patient, when only focusing on clinical trial results.…”

Section: Discussionsupporting

confidence: 83%

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 83%

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…This result is slightly higher than the incidence reported by the Danish and Swedish registries and by the German-Austrian AMLSG group [11, 13, 18]. …”

Section: Discussioncontrasting

confidence: 54%

“…Intensive chemotherapy in patients with AML secondary to previous MDS, CMML, MPN, or prior cytotoxic exposure remains unsatisfactory compared to de novo AML [13, 19]. However, our results suggest that t-AML following treatment of solid cancer has a better outcome compared to post-MDS, post-CMML, and post-LD while post-MPN AML seems to have the worst outcome.…”

Section: Discussionmentioning

confidence: 76%

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

et al. 2016

View full text Add to dashboard Cite

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently.

show abstract

“…Compared to patients with de novo AML, t-MN patients are more likely to have high-risk karyotypes, comorbidities, and poor performance status 130 . In a study that adjusted for these confounding factors, it was found that among patients 60 years or older, with a high-risk karyotype, and undergoing intensive therapy, t-MN patients had a similar outcome compared to de novo AML 130 .…”

Section: Prognosismentioning

confidence: 99%

Therapy-related myeloid neoplasms: when genetics and environment collide

2017

View full text Add to dashboard Cite

Therapy-related myeloid neoplasms (t-MN) arise as a late-effect of chemotherapy and/or radiation administered for a primary condition, typically a malignant disease, solid organ transplant, or autoimmune disease. Survival is measured in months, not years, making t-MN one of the most aggressive and lethal cancers. In this review, we discuss recent developments that reframe our understanding of the genetic and environmental etiology of t-MN. Emerging data illuminate who is at highest risk for developing t-MN, why t-MN is chemoresistant, and how we may use this information to treat and ultimately prevent this dreaded disease.

show abstract

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

Cited by 371 publications

References 36 publications

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Therapy-related myeloid neoplasms: when genetics and environment collide

Contact Info

Product

Resources

About